Archives

by in
Entry Author Date Location
Surface Oncology Raises $35M to Develop Cancer Immunotherapies 01/08/15 Boston
CART + CRISPR = 1st-Of-Its-Kind Biotech Deal From Novartis, Intellia 01/07/15 Boston
Don’t Get Comfortable: 5 Biopharma Flashpoints to Consider in 2015 01/06/15 National
Larry Corey, Cofounder of 2014 Top Biotech Juno: “It’s No Outlier” 01/05/15 Seattle
Officials Say Fuji’s Purchase of Kalon Boosts Texas’s Biotech Profile 12/22/14 Texas
Rethinking Venture Philanthropy After the Kalydeco Windfall 12/22/14 Boston
Houston’s Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO 12/18/14 Texas
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
Immunotherapy Confidence (And Audience) Abundant At ASH T-Cell Talk 12/08/14 National
With New Data, Agios Plots Quick Turn into Key Late-Stage Trials 12/07/14 Boston
Array and Novartis End Development Deal for Cancer Drug Binimetinib 12/04/14 Boulder/Denver
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind” 12/02/14 National
With Souped-Up Rituxan, Unum Plots First Foray Into T-Cell Therapy 12/01/14 Boston
With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray 11/18/14 Boston
New Research Could (Finally) Remove RNAi’s Commercial Limitations 11/17/14 National
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
What Early Looks From ASH Tell Us About Cancer Immunotherapy 11/07/14 National
Proteostasis, Astellas Join up on Genetic Disease Drugs 11/04/14 Boston
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
Aiming to Boost Innovation, Trinity Fine-Tunes Its Tech Transfer 10/30/14 National
Opsona, And Pharma Backers, Await Day of Reckoning for Kidney Drug 10/29/14 National
Pharmas, Others Bet $33M More on Aileron’s P53 Peptide Drug 10/29/14 Boston
East Coast Biotech Roundup: PureTech, Celgene, Unum, Biogen & More 10/24/14 Boston
New Atlas Startup Gets “Quartet” of Backers, $17M For Pain Drugs 10/23/14 Boston
Proteon Cuts Price, Boosts Shares to Bag $61M in IPO 10/22/14 Boston
With $24M and Pharma Backing, Ex Epizyme Prez Aims to “Raze” Tumors 10/14/14 Boston
What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure 10/07/14 Seattle
Austin Biotech Savara Nets $10M to Develop Cystic Fibrosis Drug 10/06/14 Texas
East Coast Biotech Roundup: Intarcia, Atlas, Visterra, & More 10/06/14 Boston
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies 10/06/14 Seattle
Page 2 of 15 « previous page · next page »